Literature DB >> 11306954

Further characterization of FcgammaRII and FcgammaRIII expression by cultured human mast cells.

Y Okayama1, D D Hagaman, M Woolhiser, D D Metcalfe.   

Abstract

BACKGROUND: We have reported that resting human mast cells exhibit minimal expression for FcgammaRI, and that interferon-gamma will upregulate this expression. The expression of FcgammaRII and FcgammaRIII by human mast cells remains to be fully examined.
METHODS: To investigate FcgammaRII and FcgammaRIII expression, we determined mRNA and protein expression of FcgammaRII and FcgammaRIII in human peripheral blood CD34+ derived cultured mast cells by RT-PCR and flow cytometry. The expression of FcgammaRII and FcgammaRIII in intact and permeabilized mast cells was also compared. We measured histamine release to monitor mast cell degranulation following cross-linking of FcgammaRII.
RESULTS: We found by RT-PCR that resting human mast cells exhibit mRNA for FcgammaRIIA, FcgammaRIIb1, FcgammaRIIb2 and FcgammaRIII but not FcgammaRIIC. FACS analysis of Fcgamma receptors in intact versus permeabilized mast cells showed expression of FcgammaRII to be 42.2 +/- 3.9% and this was unchanged by permeabilization. FcgammaRIII protein expression was minimal and this was also unchanged by permeabilization. Aggregation of FcgammaRII on human mast cells led to no significant degranulation as evidenced by histamine release.
CONCLUSIONS: In addition to FcgammaRI expression, human mast cells express FcgammaRIIA, FcgammaRIIb1, FcgammaRIIb2 and FcgammaRIII mRNA, and significant surface expression of FcgammaRII. Aggregation of FcgammaRII on cultured human mast cells in this model was not followed by histamine release. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306954     DOI: 10.1159/000053696

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  9 in total

Review 1.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

2.  Dengue virus selectively induces human mast cell chemokine production.

Authors:  Christine A King; Robert Anderson; Jean S Marshall
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

3.  Association of rheumatoid factor production with FcgammaRIIIa polymorphism in Taiwanese rheumatoid arthritis.

Authors:  J-Y Chen; C-M Wang; J-M Wu; H-H Ho; S-F Luo
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

Review 4.  Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity.

Authors:  Jop Jans; Marloes Vissers; Jacco G M Heldens; Marien I de Jonge; Ofer Levy; Gerben Ferwerda
Journal:  Rev Med Virol       Date:  2013-11-14       Impact factor: 6.989

Review 5.  Mast cell function: a new vision of an old cell.

Authors:  Elaine Zayas Marcelino da Silva; Maria Célia Jamur; Constance Oliver
Journal:  J Histochem Cytochem       Date:  2014-07-25       Impact factor: 2.479

Review 6.  Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions.

Authors:  Louisa K James; Stephen J Till
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

Review 7.  The monocyte-macrophage-mast cell axis in dengue pathogenesis.

Authors:  Shu-Wen Wan; Betty A Wu-Hsieh; Yee-Shin Lin; Wen-Yu Chen; Yan Huang; Robert Anderson
Journal:  J Biomed Sci       Date:  2018-11-08       Impact factor: 8.410

8.  Interferon-γ regulates growth and controls Fcγ receptor expression and activation in human intestinal mast cells.

Authors:  Gernot Sellge; Miriam Barkowsky; Sigrid Kramer; Thomas Gebhardt; Leif E Sander; Axel Lorentz; Stephan C Bischoff
Journal:  BMC Immunol       Date:  2014-07-05       Impact factor: 3.615

Review 9.  Manipulation of cell surface macromolecules by flaviviruses.

Authors:  Robert Anderson
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.